Clinical Trials Logo

Filter by:
NCT ID: NCT03737149 Active, not recruiting - Clinical trials for Osteoarthritis, Knee

A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform

Start date: October 22, 2018
Phase: N/A
Study type: Interventional

Post-market prospective, multi-center longitudinal study to determine if mobile application-guided education and exercise paired with accurate and sensitive activity monitoring, captured from consumer wearables, can provide a viable (and potentially improved) alternative to current standard of care physical therapy for hip and knee arthroplasty.

NCT ID: NCT03737110 Completed - Clinical trials for Recurrent Pericarditis

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

RHAPSODY
Start date: January 7, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.

NCT ID: NCT03736122 Not yet recruiting - Clinical trials for Malignant Pleural Effusion

A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites

Start date: January 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Malignant pleural effusion and/ or malignant ascites is generally defined by presence of malignant cells in the effusion fluid. The first-line therapies are mostly intrusive, medically demanding and inefficient, and therefore, it is important to study and develop new therapeutic option to address the unmet need. This protocol for BSG-001 is developed for the treatment of malignant pleural effusion and/ or malignant ascites. BSG-001 is an immune-modulator primarily exerts its effect via Toll-like receptor. The purpose of this study is to assess the safety and tolerability of BSG-001. All eligible subjects will receive BSG-001 for at least 12 weeks (3 cycles).

NCT ID: NCT03735810 Completed - Healthy Volunteer Clinical Trials

Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses

Start date: November 15, 2018
Phase: Phase 1
Study type: Interventional

This is a single center, randomized, double-blind, placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study is planned to assess safety, pharmacokinetics (PK), and pharmacodynamics of LBS-008 in healthy adult volunteers.

NCT ID: NCT03734679 Active, not recruiting - Clinical trials for Hemodialysis Access Failure

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon (AVess FIH)

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and performance of the SurVeil DCB in subjects with obstructive lesions of arteriovenous fistulae for hemodialysis.

NCT ID: NCT03734640 Recruiting - Clinical trials for Acute Ischemic Stroke Patients Receiving Reperfusion Therapy

Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

Start date: April 28, 2021
Phase: N/A
Study type: Interventional

OPTIMISTmain is an investigator-initiated and conducted, international, multicentre, stepped wedge cluster randomized controlled trial comparing the effects of different intensities of nursing care monitoring for patients with acute ischemic stroke of mild severity and without critical care needs after IV-tPA.

NCT ID: NCT03733392 Completed - Clinical trials for Ventricular Tachycardia

Advisor HD Grid Observational Study

Start date: January 11, 2019
Phase:
Study type: Observational

The aim of this study is to quantify and characterize the outcomes of radiofrequency (RF) ablation after, and the utility of electroanatomical mapping with the Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ (hereafter called "HD Grid") and EnSite Precision™ Cardiac Mapping System (SV 2.2 or higher, hereafter called "EnSite Precision") with HD Wave Solution™ voltage mapping (hereafter called "HD Wave Solution") in subjects with persistent atrial fibrillation (PersAF) or ventricular tachycardia (VT) in real-world clinical settings.

NCT ID: NCT03733301 Completed - Atopic Dermatitis Clinical Trials

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

BREEZE-AD7
Start date: November 16, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.

NCT ID: NCT03732820 Active, not recruiting - Clinical trials for Metastatic Castration-resistant Prostate Cancer

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Start date: October 31, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.

NCT ID: NCT03732807 Completed - Alopecia Areata Clinical Trials

PF-06651600 for the Treatment of Alopecia Areata

ALLEGRO-2b/3
Start date: December 3, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.